| Cat. No. |
Product Name |
Information |
| PC-49132 |
Dalmelitinib
|
Dalmelitinib is a potent, selective c-Met tyrosine kinase inhibitor with IC50 of 0.7 nM, inhibits cell growth of gastric cells SNU5 with IC50 of 2.0 nM, binds to the ATP-binding region of c-MET kinase. |
| PC-35732 |
PLB-1001
|
PLB-1001 (Bozitinib, PLB1001, CBI-3103, CBT-101) is a potent, highly selective, ATP-competitive, BBB-permeable MET kinase inhibitor, potently inhibits MET activity by 95.1% at 2 uM. |
| PC-43511 |
Capmatinib
|
Capmatinib (INCB-28060, INC-280) is a highly potent, selective, ATP competitive inhibitor of c-MET kinase with IC50 of 0.13 nM. |
| PC-43478 |
MK-8033 hydrochloride
|
MK-8033 is a potent, specific, dual c-Met/Ron kinases inhibitor with IC50 of 1/7 nM, also potently inhibits oncogenic c-Met activation loop mutants Y1230C, Y1230H and Y1235D with IC50 of 0.6-1.2 nM. |
| PC-43477 |
MK-8033
|
MK-8033 is a potent, specific, dual c-Met/Ron kinases inhibitor with IC50 of 1/7 nM, also potently inhibits oncogenic c-Met activation loop mutants Y1230C, Y1230H and Y1235D with IC50 of 0.6-1.2 nM. |
| PC-63402 |
JNJ-38877618
|
JNJ-38877618 (OMO-1) is a novel potent, highly selective, orally bioavailable c-Met tyrosine kinase inhibitor with Kd of 1.2, 2.1 and 21 nM for WT, M1250T and Y1235D mutants MET, respectively. |
| PC-42888 |
BMS 777607
|
BMS 777607 (ASLAN002) is a potent, selective, orally efficacious inhibitor of Met kinase with IC50 of 3.9 nM, also potently inhibits Ron, Axl, Tyro-3 and Mer (IC50<15 nM), 40-fold selectivity over Lck, VEGFR-2 and TrkA/B. |
